The mission of the AIDS Clinical Trials Group (ACTG) is to develop and conduct scientifically rigorous translational research and therapeutic clinical trials to: 1) investigate the viral and immune pathogenesis of HIV-1 infection and its complications;2) evaluate novel therapeutic agents and the most effective approaches and strategies for the use of existing agents to treat HIV-1 infection;3) evaluate interventions and strategies to treat and prevent HIV-related opportunistic infections, co-infections, complications of therapies, and other HIV-1-related co-morbidities, and 4) publish and disseminate the findings from these studies for the purpose of improving clinical care, preventing or delaying HIV disease progression, and reducing or eliminating the morbidity and mortality associated with HIV-1 infection and its associated complications. In this application the ACTG proposes a comprehensive, integrated clinical and translational research program that addresses five of the six scientific areas outlined under this RFA: 1) Translational Research and Drug Development;2) Optimization of Clinical Management, including Co-Infection;3) Vaccine Research and Development;4) Prevention of Mother to Child Transmission, and 5) Prevention of HIV Infection. An Oral Health program will be undertaken in collaboration with investigators supported by the National Institute of Dental and Craniofacial Research. This program will be conducted in collaboration with the HIV Prevention Trials Network (HPTN), the HIV Vaccine Trials Network (HPTN), the IMPAACT network and the Microbicide Trials Network (MTN). The proposed research agenda as well as the Group Leadership and organizational structure reflect the worldwide impact of the HIV epidemic. We propose to conduct the work using a network of 72 clinical research sites in the United States and 12 countries in Africa, Asia, Latin America and the Caribbean. The network is actively supported by an integrated network of Core Laboratories with broad expertise in virology, pharmacology, immunology, and genomics. The ACTG Operations Center, located in Silver Spring, MD, provides key operational, administrative, and fiscal support. Statistical expertise and data management resources are provided by the Statistics and Data Management Center in Boston, MA and Buffalo, NY. CORE (P.I. Benson, Constance) CORE: Translational Research/Drug Development

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI068636-06
Application #
8096739
Study Section
Special Emphasis Panel (ZAI1-TS-A (J1))
Program Officer
Ojumu, Akinlolu O
Project Start
2006-06-29
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
6
Fiscal Year
2011
Total Cost
$26,127,945
Indirect Cost
Name
Social and Scientific Systems, Inc.
Department
Type
DUNS #
091340943
City
Silver Spring
State
MD
Country
United States
Zip Code
20910
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications. Clin Pharmacol Drug Dev 6:135-139
Muhammad, Josh; Chan, Ellen S; Brown, Todd T et al. (2017) Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation. Open Forum Infect Dis 4:ofx210
Tam, Edward; Luetkemeyer, Anne F; Mantry, Parvez S et al. (2017) Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver Int :
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med 167:384-393
Qi, Li; Sun, Yanqing; Gilbert, Peter B (2017) Generalized semiparametric varying-coefficient model for longitudinal data with applications to adaptive treatment randomizations. Biometrics 73:441-451
Sherman, Kenneth E; Kang, Minhee; Sterling, Richard et al. (2017) Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol 9:217-223
Tassiopoulos, Katherine; Abdo, Mona; Wu, Kunling et al. (2017) Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS 31:2287-2294
Gandhi, Rajesh T; McMahon, Deborah K; Bosch, Ronald J et al. (2017) Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog 13:e1006285
Gay, Cynthia L; Bosch, Ronald J; Ritz, Justin et al. (2017) Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. J Infect Dis 215:1725-1733
Chang, Ming; Wong, Audrey J S; Raugi, Dana N et al. (2017) Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm. J Clin Virol 86:56-61

Showing the most recent 10 out of 461 publications